SCHEMBL6355737

SCHEMBL6355737

CC(=O)NCCOc1ccc(C2(O)CCCC2NS(=O)(=O)C(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.44
MTNR1B P49286 3/20 0.44
USP2 O75604 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HRH3 Q9Y5N1 1/20 0.36
PDK2 Q15119 1/20 0.36
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
EPHX2 P34913 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 1/20 0.34
ACACB O00763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345788 0.97 MTNR1A (0.43) MTNR1AMTNR1BUSP2ALOX15TSHR
SCHEMBL6348951 0.89 HRH3 (0.35) TSHRALDH1A1MEN1KMT2AHRH3
SCHEMBL6346460 0.87 MTNR1A (0.43) MTNR1AMTNR1BUSP2ALOX15TSHR
SCHEMBL6345477 0.87 ALDH1A1 (0.41) TSHRALDH1A1MEN1KMT2AHRH3
SCHEMBL6349722 0.86 KDM4E (0.37) TSHRALDH1A1MEN1KMT2AHRH3
SCHEMBL6345330 0.86 MEN1 (0.37) TSHRALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL6355740 0.85 ALDH1A1 (0.45) MTNR1AMTNR1BUSP2ALOX15TSHR
SCHEMBL6350038 0.85 MTNR1A (0.42) MTNR1AMTNR1BUSP2ALOX15TSHR
SCHEMBL6344424 0.84 ALDH1A1 (0.40) TSHRALDH1A1MEN1KMT2AHRH3
SCHEMBL6356775 0.83 ALDH1A1 (0.36) TSHRALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP disclosed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 MTNR1A 212/4885MTNR1B 336/4885USP2 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.